Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

706 articles

Showing 25–48 of 72 articles · Keyword: PLGA Clear keyword

Frontiers in Bioengineering and Biotechnology2020ResearchDrug Delivery

25. Melanoma Peptide MHC Specific TCR Expressing T-Cell Membrane Camouflaged PLGA Nanoparticles for Treatment of Melanoma Skin Cancer

Serkan Yaman, Harish Ramachandramoorthy, Gizem Oter, Daria Zhukova, Tam Nguyen, Manoj K. Sabnani, Jon A. Weidanz, Kytai T. Nguyen

Melanoma is an aggressive skin cancer with limited treatment efficacy due to non-specific drug targeting, severe side effects, and multidrug resistance. Current cell-based immunotherapies are costly, complex, and carry long-term autoimmune risks. There is a need for a targeted, biocompatible drug delivery system that…

Read the article
International Immunopharmacology2020ReviewNon-viral Gene Delivery

26. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy

Hashemi V, Farhadi S, Ghasemi Chaleshtari M, Et Al.

Dendritic cell (DC)-based cancer immunotherapy has shown impressive outcomes, including the first FDA-approved anti-cancer vaccine, but clinical application faces challenges such as limited durable responses, antigen selection issues, and immunosuppressive tumour microenvironments. Nanoparticles (NPs) are promising…

Read the article
2020ReviewNon-viral Gene Delivery

27. Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals

Zeb A, Rana I, Choi H-I, Et Al.

Biopharmaceuticals have become clinically and commercially important due to their specificity, potency, targeting ability, and reduced side effects, but their macromolecular structure and intrinsic instability make formulation and administration challenging; parenteral delivery remains the only viable option in most…

Read the article
Nanomaterials2020ReviewDrug Delivery

28. Stealth Coating of Nanoparticles in Drug-Delivery Systems

Fam Sy, Chee Cf, Yong Cy, Ho Kl, Mariatulqabtiah Ar, Tan Ws.

Nanoparticles (NPs) interact extensively with plasma proteins after intravenous administration and are rapidly cleared by the mononuclear phagocyte system (MPS) or complement system, causing premature drug release at off-target sites. A stealth coating layer can improve blood circulation half-life by escaping immune…

Read the article
Acta Biomaterialia2019ResearchNon-viral Gene Delivery

29. Injectable PLGA microspheres with tunable magnesium ions release for promoting bone regeneration

Zuoying Yuan, Pengfei Wei, Yiqian Huang, Wenxin Zhang, Fuyu Chen, Xu Zhang, Jianping Mao, Dafu Chen, Qing Cai, Xiaoping Yang

Magnesium ions (Mg²⁺) promote bone regeneration, but their effects are strongly concentration-dependent: too little has minimal effect, while excess Mg²⁺ can impair osteoblast activity and bone metabolism. There is no well-established bone tissue engineering scaffold that precisely controls local Mg²⁺ release…

Read the article
2019ReviewNon-viral Gene Delivery

30. Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry

Gheibi Hayat Sm, Bianconi V, Pirro M, Sahebkar A.

Biomaterials and nanoparticles (NPs) used for medical purposes often trigger immune recognition, inflammation, and rapid clearance by the reticuloendothelial system (RES)/mononuclear phagocyte system (MPS). PEGylation and cell-membrane camouflaging are common stealth strategies, but they have limitations, including…

Read the article
Journal of Pharmaceutical Investigation2019ReviewDrug Delivery

31. Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)poly(lactic‑co‑glycolic acid) micro and nanoparticles

PLA and PLGA are FDA-approved, biodegradable polymers widely used for micro- and nanoparticle drug delivery, but their clinical performance depends on biocompatibility, degradation behaviour, and drug-release control. This review addresses the need to understand PLA/PLGA tissue responses, degradation pathways…

Read the article
Nanoscale2019ReviewDrug Delivery

32. Polymer nanoparticles for the intravenous delivery of anticancer drugs the checkpoints on the road from the synthesis to clinical translation

Ferrari, R.; Sponchioni, M.; Morbidelli, M.; Moscatelli, D

Many polymer-based nanoparticle formulations fail before or during clinical trials. This review identifies the key checkpoints a nanocarrier must satisfy after intravenous injection — biocompatibility, drug loading/release, storage stability, biodistribution, target selectivity, cellular internalisation, and…

Read the article
RSC Advances2019ReviewDrug Delivery

33. Microfluidic Assisted Synthesis of PLGA Drug Delivery Systems

Sima Rezvantalab And Mostafa Keshavarz Moraveji

PLGA is a biocompatible, biodegradable copolymer widely used in drug delivery systems (DDS), but conventional bulk synthesis methods suffer from poor control over particle size, broad size distribution, low drug loading/encapsulation efficiency, and burst release. Microfluidic systems offer a tightly controlled…

Read the article
Journal of Visualized Experiments (JoVE)2018ResearchNon-viral Gene Delivery

34. Fabrication of Anisotropic Polymeric Artificial Antigen Presenting Cells for CD8+ T Cell Activation

Elana Ben-Akiva, Kelly R. Rhodes, Randall A. Meyer, Jordan J. Green

Artificial antigen-presenting cells (aAPCs) are promising for immune modulation, and anisotropic (ellipsoidal) particles have shown improved T-cell stimulation over spherical particles. However, widely used methods for generating anisotropic particles, such as thin-film stretching, can be difficult to implement…

Read the article
Colloids and Surfaces B: Biointerfaces2018ResearchDrug Delivery

35. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo

Amirhossein Bahreyni, Mona Alibolandi, Mohammad Ramezani, Atefeh Sarafan Sadeghi, Khalil Abnous, Seyed Mohammad Taghdisi

Conventional chemotherapy for breast and colon cancers suffers from low specificity, rapid drug clearance, and severe toxic side effects on healthy tissues, while chemoresistance and metastasis remain major causes of cancer-related mortality. There is an unmet need for targeted delivery systems that can co-deliver…

Read the article
International Journal of Pharmaceutics2018ReviewNon-viral Gene Delivery

36. Nanoparticles for dendritic cell-based immunotherapy

Tran Th, Tran Ttp, Nguyen Ht, Phung Cd, Jeong J-H, Stenzel Mh, Jin Sg, Yong Cs, Truong Dh, Kim Jo.

Dendritic cell (DC)-based cancer immunotherapy is promising but limited by poor antigen immunogenicity, weak stability, and short in vivo half-life. Nanotechnology can protect antigens and adjuvants from premature degradation, enhance delivery to DCs, and improve therapeutic T cell responses. This review summarises…

Read the article
Annual Review of Chemical and Biomolecular Engineering2018ReviewNon-viral Gene Delivery

37. Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments

Karlsson, J.; Vaughan, H. J.; Green, J. J

Biodegradable polymeric nanoparticles have great potential to improve cancer therapy by enabling targeted delivery, triggered release, and reduced off-target toxicity. This review addresses how such nanocarriers can be engineered to overcome systemic, organ-level, and cellular barriers and to target cancer cells…

Read the article
Frontiers in Pharmacology2018ReviewDrug Delivery

38. PLGA-Based Nanoparticles in Cancer Treatment

Sima Rezvantalab, Natascha Ingrid Drude, Mostafa Keshavarz Moraveji, Nihan Güvener, Emily Kate Koons, Yang Shi, Twan Lammers, Fabian Kiessling

PLGA-based nanoparticles are widely investigated for cancer therapy, but their clinical translation remains limited. A consolidated overview was needed of how PLGA NP physicochemical properties, biological behaviour, targeting strategies, and combination therapies interact—and why promising preclinical results have…

Read the article
Theranostics2017ReviewNon-viral Gene Delivery

39. Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs

Chao Wang, Wujin Sun, Yanqi Ye, Hunter N. Bomba, Zhen Gu

Immune cell/organ therapies based on manipulation, infusion, and implantation of autologous or allogeneic cells/organs are costly, time-consuming, and sometimes limited in clinical effectiveness. Biomimetic materials and strategies offer an alternative by enabling artificial immune cells and lymphoid organs that are…

Read the article
Theranostics2017ResearchNon-viral Gene Delivery

40. Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo

Xi Zhu, Wei Tao, Danny Liu, Jun Wu, Zilei Guo, Xiaoyuan Ji, Zameer Bharwani, Lili Zhao, Xiaoping Zhao, Omid C. Farokhzad, Jinjun Shi

Surface PEGylation of nanoparticles (NPs) improves circulation time and tumour accumulation but also hinders intracellular delivery, creating the "PEG dilemma" for siRNA therapeutics. While stimuli-responsive de-PEGylation strategies exist, they add complexity to NP design and synthesis. A tunable, serum…

Read the article
Nature Communications2017ResearchNon-viral Gene Delivery

41. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Daniela Schmid, Chun Gwon Park, Christina A. Hartl, Nikita Subedi, Adam N. Cartwright, Regina Bou Puerto, Yiran Zheng, James Maiarana, Gordon J. Freeman, Kai W. Wucherpfennig, Darrell J. Irvine, Michael S. Goldberg

Systemic immune stimulation for cancer immunotherapy is associated with autoimmune-type pathologies, as the doses required to break immune tolerance can invoke undesired host-vs.-host effects. Targeting endogenous immune cell subsets in the circulation—which actively migrate into tumours—could concentrate…

Read the article
International Journal of Pharmaceutics2017ResearchNon-viral Gene Delivery

42. Nasal Vaccination with Poly(β-amino ester)–Poly(D,L-lactide-co-glycolide) Hybrid Nanoparticles

Genada Sinani, Melike Sessevmez, M. Koray Gök, Saadet Özgümüş, Alper Okyar, H. Oya Alpar, Erdal Cevher

Mucosal vaccination can stimulate both mucosal and systemic immunity, but free protein antigens generally induce poor systemic immune responses and require adjuvants. There is a need for a safe, effective nasal vaccine carrier that improves antigen stability, uptake, and immunogenicity, especially for poorly…

Read the article
Materials2017ReviewNon-viral Gene Delivery

43. Poly(Lactic-co-Glycolic Acid) Applications and Future Prospects for Periodontal Tissue Regeneration

Sun, X.; Wu, G.; Xu, C.; Ye, Q.; Wang, C

Periodontitis causes irreversible destruction of periodontal tissues, and regeneration requires biomaterials with suitable mechanical, degradation, and biological properties. PLGA is attractive for periodontal regeneration because of its biocompatibility, tunable degradation, and processability, but its…

Read the article
Advanced Drug Delivery Reviews2016ReviewNon-viral Gene Delivery

44. Gene Delivery Nanoparticles to Modulate Angiogenesis

Jayoung Kim, Adam C. Mirando, Aleksander S. Popel, Jordan J. Green

Angiogenesis is normally balanced by pro- and anti-angiogenic factors, but imbalance leads to aberrant angiogenesis in ischaemia, tissue regeneration, cancer, and neovascular age-related macular degeneration (wet AMD). Gene therapy is a promising strategy to introduce exogenous nucleic acids that express or silence…

Read the article
Drug Delivery2016ResearchDrug Delivery

45. Nanostructured Lipid Carriers, Solid Lipid Nanoparticles, and Polymeric Nanoparticles—Which Kind of Drug Delivery System Is Better for Glioblastoma Chemotherapy?

Jie Qu, Liangqiao Zhang, Zhihua Chen, Guohua Mao, Ziyun Gao, Xianliang Lai, Xingen Zhu, Jianming Zhu

Glioblastoma multiforme (GBM) has a poor prognosis due to limited drug delivery across the blood–brain barrier (BBB), therapeutic resistance, and recurrence. Nanocarriers may improve temozolomide (TMZ) delivery, but it is unclear which nanocarrier type—polymeric nanoparticles (PNPs), solid lipid nanoparticles (SLNs)…

Read the article
Journal of Controlled Release2016ResearchDrug Delivery

46. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on he

Cong Zhang, Tong An, Dan Wang, Guoyun Wan, Mingming Zhang, Hemei Wang, Sipei Zhang, Rongshan Li, Xiaoying Yang, Yinsong Wang

Hepatocellular carcinoma (HCC) has poor prognosis and limited effective systemic therapy. Combination antiangiogenesis and chemotherapy with paclitaxel (PTX) and combretastatin A4 (CA4) is synergistic, but both drugs have poor solubility, lack tumour targeting, and cause systemic toxicity. A tumour…

Read the article
Advanced Drug Delivery Reviews2016ReviewNon-viral Gene Delivery

47. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Suk, J. S.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L. M

PEGylation is widely used to improve nanoparticle drug and gene delivery by reducing aggregation, opsonisation, and phagocytic clearance, thereby prolonging circulation. However, the field lacks a consolidated understanding of how PEG molecular weight, surface density, conformation, core properties, administration…

Read the article
Advanced Drug Delivery Reviews2015ReviewNon-viral Gene Delivery

48. In Vivo Delivery of miRNAs for Cancer Therapy: Challenges and Strategies

Yunching Chen, Dong-Yu Gao, Leaf Huang

miRNAs can simultaneously regulate multiple cancer-related genes, making them attractive therapeutic agents or targets. However, efficient, specific, and safe systemic delivery of therapeutic miRNAs in vivo remains a major challenge due to rapid degradation, poor tumour penetration, immunotoxicity, endosomal…

Read the article
Articles — page 2 | Brilliant Blue Biosciences